• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

    3/14/25 8:35:00 AM ET
    $CGTX
    $COCP
    $FBLG
    $PDSB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CGTX alert in real time by email

    NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum, held March 13th are now available for online viewing.

    REGISTER NOW AT: https://bit.ly/3DIWqav

    The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may download investor materials from the company's resource section.

    Select companies are accepting 1x1 management meeting requests through March 18th.

    To facilitate investor relations scheduling and to view a complete calendar of Virtual Investor Conferences, please visit www.virtualinvestorconferences.com.

    March 13th

    PresentationTicker(s)
    Cognition Therapeutics, Inc.(NASDAQ:CGTX)
    Biophytis SA(OTC:BPTSY, FP: ALBPS))
    Avicanna Inc.(OTCQX:AVCNF, TSX:AVCN)
    Psy Therapeutics, Inc.Private
    Cocrystal Pharma, Inc.(NASDAQ:COCP)
    NervGen Pharma Corp.(OTCQB:NGENF, TSXV:NGEN)
    FibroBiologics, Inc.(NASDAQ:FBLG)
    Telescope Innovations Corp.(OTCQB:TELIF, CSE:TELI)
    Rafarma Pharmaceuticals, Inc.(OTC:RAFA)
    Izotropic Corporation(OTCQB:IZOZF, CSE:IZO)
    PDS Biotechnology Corporation(NASDAQ:PDSB)
    LadRx Corporation(OTCQB:LADX)
    Tonix Pharmaceuticals Holding Corp.(NASDAQ:TNXP)
    Hemostemix, Inc.(OTCQB:HMTXF, TSXV:HEM)



    About Virtual Investor Conferences
    ®

    Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

    Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

    Media Contact: 

    OTC Markets Group Inc. +1 (212) 896-4428, [email protected]

    Virtual Investor Conferences Contact:

    John M. Viglotti

    SVP Corporate Services, Investor Access

    OTC Markets Group

    (212) 220-2221

    [email protected]



    Primary Logo

    Get the next $CGTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CGTX
    $COCP
    $FBLG
    $PDSB

    CompanyDatePrice TargetRatingAnalyst
    Cognition Therapeutics Inc.
    $CGTX
    12/19/2024$1.00 → $1.50Neutral → Buy
    B. Riley Securities
    FibroBiologics Inc.
    $FBLG
    12/12/2024$12.00Buy
    Rodman & Renshaw
    FibroBiologics Inc.
    $FBLG
    10/30/2024$12.00Buy
    H.C. Wainwright
    FibroBiologics Inc.
    $FBLG
    9/24/2024$12.00Buy
    Maxim Group
    Cognition Therapeutics Inc.
    $CGTX
    7/30/2024Overweight → Neutral
    Cantor Fitzgerald
    PDS Biotechnology Corporation
    $PDSB
    11/1/2022$10.00Buy
    B. Riley Securities
    Tonix Pharmaceuticals Holding Corp.
    $TNXP
    4/18/2022Outperform
    Noble Capital Markets
    Cognition Therapeutics Inc.
    $CGTX
    11/3/2021$27.00Buy
    B. Riley Securities
    More analyst ratings

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Caggiano Anthony was granted 65,000 shares and covered exercise/tax liability with 20,281 shares, increasing direct ownership by 11% to 463,273 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    7/31/25 4:24:07 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Financial Officer Doyle John Brendan was granted 30,000 shares and covered exercise/tax liability with 9,360 shares, increasing direct ownership by 5% to 425,350 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    7/31/25 4:23:52 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    CEO & President Ricciardi Lisa was granted 75,000 shares and covered exercise/tax liability with 23,400 shares, increasing direct ownership by 6% to 938,666 units (SEC Form 4)

    4 - COGNITION THERAPEUTICS INC (0001455365) (Issuer)

    7/31/25 4:23:32 PM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cognition Therapeutics upgraded by B. Riley Securities with a new price target

    B. Riley Securities upgraded Cognition Therapeutics from Neutral to Buy and set a new price target of $1.50 from $1.00 previously

    12/19/24 7:33:00 AM ET
    $CGTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

    Rodman & Renshaw initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    12/12/24 8:54:24 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on FibroBiologics with a new price target

    H.C. Wainwright initiated coverage of FibroBiologics with a rating of Buy and set a new price target of $12.00

    10/30/24 6:37:36 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administratio

    8/15/25 3:44:52 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biotech Stocks Rally as Oncology Market Targets $866B by 2034

    Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts that stand to potentially harm the national battle against cancer, it appears that the private sector continues to step up, with hundreds of millions of VC dollars pouring into oncology ventures so far in 2025. While there has been a recent victory in the Senate to restore $15 million for the Pancreatic Cancer Research Program (PCARP), the prior elimination of the only federal program dedicated solely to researching pancreatic cancer served as a stark reminder of these ongoing funding challenges. This dyn

    8/14/25 12:30:00 PM ET
    $IOBT
    $OLMA
    $ONCY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and treatment," said Sam Lee, Ph.D., Cocrystal's President and co-CEO. "We are encouraged by the favorable

    8/14/25 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    SEC Filings

    View All

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    8/18/25 7:01:21 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Holding Corp. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Tonix Pharmaceuticals Holding Corp. (0001430306) (Filer)

    8/15/25 5:23:40 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Cocrystal Pharma Inc.

    10-Q - Cocrystal Pharma, Inc. (0001412486) (Filer)

    8/14/25 8:01:10 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Scientific Officer Khoja Hamid bought $16,800 worth of shares (20,000 units at $0.84), increasing direct ownership by 178% to 31,250 units (SEC Form 4)

    4 - FibroBiologics, Inc. (0001958777) (Issuer)

    5/27/25 5:56:53 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Lederman Seth bought $86,200 worth of shares (4,000 units at $21.55), increasing direct ownership by 80,000% to 4,005 units (SEC Form 4)

    4 - Tonix Pharmaceuticals Holding Corp. (0001430306) (Issuer)

    5/15/25 5:08:40 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Freitag Gregory Gene bought $25,000 worth of shares (15,060 units at $1.66), increasing direct ownership by 33% to 61,213 units (SEC Form 4)

    4 - PDS Biotechnology Corp (0001472091) (Issuer)

    3/3/25 4:45:42 PM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Leadership Updates

    Live Leadership Updates

    View All

    FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    HOUSTON, July 31, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced second quarter 2025 financial results and provided a corporate update. Recent Highlights Successfully closed third $5 million tranche of a $25 million total financing, with proceeds used to advance research and development efforts and support the upcoming Phase 1/2 clinical trial in diabetic foot ulcers (DFUs).Strengthened leadership team with the appointment of

    7/31/25 4:30:00 PM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tonix Pharmaceuticals Announces Appointment of Commercial Industry Veteran, James "Jim" Hunter, to Board of Directors

    Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year CHATHAM, N.J., June 13, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company), a fully-integrated biotechnology company with marketed products and a pipeline of

    6/13/25 7:00:00 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

    HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 275+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the appointment of Jason D. Davis, CPA, as Chief Financial Officer, effective immediately. Mr. Davis brings extensive experience in corporate finance, capital markets, and SEC reporting, with a proven track record of successfully leading companies through critical growth phases, including IPOs and capital raising initiatives. His appointment comes as FibroBiologic

    6/9/25 8:30:00 AM ET
    $FBLG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Financials

    Live finance-specific insights

    View All

    Tonix Pharmaceuticals Announces FDA Approval of Tonmya™ (cyclobenzaprine HCl sublingual tablets) for the Treatment of Fibromyalgia

    Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 years Fibromyalgia is a chronic pain condition that affects more than 10 million adults in the U.S. who are mostly women Two Pivotal Phase 3 studies demonstrated Tonmya significantly reduced fibromyalgia pain compared to placebo; generally well tolerated Commercial availability of Tonmya is expected in the fourth quarter Company to host webcast and conference call on Monday August 18, 2025 at 8:30 AM ET CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administratio

    8/15/25 3:44:52 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cocrystal Pharma Reports Second Quarter 2025 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

    Favorable CDI-988 Phase 1 safety and tolerability reported Challenge study with CDI-988 as a norovirus preventive and treatment planned later this year BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (NASDAQ:COCP) ("Cocrystal" or the "Company") reports financial results for the three and six months ended June 30, 2025, and provides updates on its antiviral product pipeline, upcoming milestones and business activities. "Preparations are underway for a Phase 1b norovirus challenge study to evaluate our potent, oral antiviral candidate CDI-988 as a prophylaxis and treatment," said Sam Lee, Ph.D., Cocrystal's President and co-CEO. "We are encouraged by the favorable

    8/14/25 8:00:00 AM ET
    $COCP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update

    Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 13, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today provided a business update and reported financial results for the second quarter ended June 30, 2025. "Our second quarter of 2025 and recent weeks have been a productive period for PDS Biotech, highlighted by the continued progress in our VERSATILE-003 Phase 3 clinical trial eval

    8/13/25 7:00:00 AM ET
    $PDSB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CGTX
    $COCP
    $FBLG
    $PDSB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:42:22 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    11/14/24 4:40:17 PM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tonix Pharmaceuticals Holding Corp.

    SC 13G/A - Tonix Pharmaceuticals Holding Corp. (0001430306) (Subject)

    10/16/24 9:01:20 AM ET
    $TNXP
    Biotechnology: Pharmaceutical Preparations
    Health Care